Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2008 5
2009 5
2010 5
2011 2
2012 2
2013 2
2014 5
2015 2
2016 2
2017 2
2018 1
2019 2
2020 1
2021 8
2022 3
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, Fujiwara K, Vergote I, Colombo N, Mäenpää J, Selle F, Sehouli J, Lorusso D, Guerra Alía EM, Reinthaller A, Nagao S, Lefeuvre-Plesse C, Canzler U, Scambia G, Lortholary A, Marmé F, Combe P, de Gregorio N, Rodrigues M, Buderath P, Dubot C, Burges A, You B, Pujade-Lauraine E, Harter P; PAOLA-1 Investigators. Ray-Coquard I, et al. N Engl J Med. 2019 Dec 19;381(25):2416-2428. doi: 10.1056/NEJMoa1911361. N Engl J Med. 2019. PMID: 31851799 Clinical Trial.
Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer.
Leman R, Muller E, Legros A, Goardon N, Chentli I, Atkinson A, Tranchant A, Castera L, Krieger S, Ricou A, Boulouard F, Joly F, Boucly R, Dumont A, Basset N, Coulet F, Chevalier LM, Rouleau E, Leitner K, González-Martin A, Gargiulo P, Lück HJ, Genestie C; PAOLA-1 investigators; Ray-Coquard I, Pujade-Lauraine E, Vaur D. Leman R, et al. Clin Cancer Res. 2023 Nov 1;29(21):4419-4429. doi: 10.1158/1078-0432.CCR-23-0898. Clin Cancer Res. 2023. PMID: 37756555 Free PMC article.
Anti-idiotypic antibody abagovomab in advanced ovarian cancer.
Bauerschlag DO, Schem C, Baumann K, Harter P, Hilpert F, Wagner U, du Bois A, Pfisterer J. Bauerschlag DO, et al. Future Oncol. 2008 Dec;4(6):769-73. doi: 10.2217/14796694.4.6.769. Future Oncol. 2008. PMID: 19086842 Review.
Nectin-4 as Blood-Based Biomarker Enables Detection of Early Ovarian Cancer Stages.
Rogmans C, Feuerborn J, Treeck L, Tribian N, Flörkemeier I, Arnold N, Weimer JP, Maass N, Jansen P, Lieb W, Dempfle A, Bauerschlag DO, Hedemann N. Rogmans C, et al. Among authors: bauerschlag do. Cancers (Basel). 2022 Nov 29;14(23):5867. doi: 10.3390/cancers14235867. Cancers (Basel). 2022. PMID: 36497350 Free PMC article.
ADAM17 inhibition enhances platinum efficiency in ovarian cancer.
Hedemann N, Rogmans C, Sebens S, Wesch D, Reichert M, Schmidt-Arras D, Oberg HH, Pecks U, van Mackelenbergh M, Weimer J, Arnold N, Maass N, Bauerschlag DO. Hedemann N, et al. Among authors: bauerschlag do. Oncotarget. 2018 Mar 23;9(22):16043-16058. doi: 10.18632/oncotarget.24682. eCollection 2018 Mar 23. Oncotarget. 2018. PMID: 29662625 Free PMC article.
Primary pulmonary choriocarcinoma: case report and review of the literature.
Serno J, Zeppernick F, Jäkel J, Schrading S, Maass N, Meinhold-Heerlein I, Bauerschlag DO. Serno J, et al. Among authors: bauerschlag do. Gynecol Obstet Invest. 2012;74(2):171-6. doi: 10.1159/000336784. Epub 2012 Jun 23. Gynecol Obstet Invest. 2012. PMID: 22738859 Review.
ADAM17-A Potential Blood-Based Biomarker for Detection of Early-Stage Ovarian Cancer.
Rogmans C, Kuhlmann JD, Hugendieck G, Link T, Arnold N, Weimer JP, Flörkemeier I, Rambow AC, Lieb W, Maass N, Bauerschlag DO, Hedemann N. Rogmans C, et al. Among authors: bauerschlag do. Cancers (Basel). 2021 Nov 6;13(21):5563. doi: 10.3390/cancers13215563. Cancers (Basel). 2021. PMID: 34771725 Free PMC article.
41 results